Development and Validation of UV-Visible Spectrophotometric Method for Estimation of Dexlansoprazole
Abstract
Aim: The Proposed study aimed to develop and validate a simple, accurate, precise and cost-effective UV-Visible spectrophotometric method for the estimation of Dexlansoprazole in bulk as well formulation.
Methods: This method for Dexlansoprazole was developed using water containing 40% acetonitrile as solvent system. After development, proposed method was validated using ICH Q2 (R1) guidelines. Dexlansoprazole solutions were scanned across the UV-visible range to identify its wavelength of maximum absorbance. The linearity of the method was established using seven calibration standards over a concentration range of 1–25 μg/mL. Three different quality control standard solutions of the Dexlansoprazole were used for establishing the accuracy and precision of the proposed method. Validity of the proposed method was established on the basis of accuracy, precision, robustness, ruggedness, limit of detection (LOD), and limit of quantitation (LOQ).
Results: The Dexlansoprazole when dissolved in water containing 40% acetonitrile showed maximum absorbance at 282 nm. The developed method demonstrated excellent linearity across the concentration range of 1–25 μg/mL, with a correlation coefficient (r²) of 0.999. The intra-day accuracy of the proposed method in terms of % Difference was in the range of −2.04 to +2.63 whereas the inter-day accuracy was in the range of −2.04 to + 2.12. The intra-day precision of the proposed UV–Visible spectrophotometric method in terms of % RSD was found to be in between 1.31 to 1.73 whereas the inter-day precision values were in between 1.59 to 2.00. The variation (% RSD) during the robustness and ruggedness studies of the proposed UV–Visible spectrophotometric method was found be below 2%. The limit of detection (LOD) and limit of quantitation (LOQ) of the proposed UV–Visible spectrophotometric method was found to be 0.1008 μg/mL and 0.3058 μg/mL respectively, ensuring adequate sensitivity for routine quality control analysis. Proposed method was successfully used for the estimation of Dexlansoprazole in formulation as well as bulk.
Conclusion: A simple, precise, yet cost-effective UV-visible spectrophotometric method was successfully developed for the estimation of Dexlansoprazole. The method utilized a solvent with an economical percentage of the organic phase in aqueous media. The validated UV-Visible method can be efficiently employed for estimating Dexlansoprazole.
Keywords:
Dexlansoprazole, UV-Visible spectrophotometry, ICH guidelinesDOI
https://doi.org/10.22270/jddt.v15i8.7332References
1. Skrzydło-Radomańska B, Radwan P. Dexlansoprazole - A new-generation proton pump inhibitor. Vol. 10, Przeglad Gastroenterologiczny. Termedia Publishing House Ltd.; 2015. p. 191-6. https://doi.org/10.5114/pg.2015.56109 PMid:26759624 PMCid:PMC4697039
2. Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Current medical research and opinion. 2009 Mar 1;25(3):627-38. https://doi.org/10.1185/03007990802693883 PMid:19232037
3. Fass R, Johnson DA, Orr WC, Han C, Mody R, Stern KN, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. American Journal of Gastroenterology. 2011 Mar;106(3):421-31. https://doi.org/10.1038/ajg.2010.458 PMid:21224838
4. Metz DC, Vakily M, Dixit T, Mulford D. dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Alimentary pharmacology & therapeutics. 2009 May;29(9):928-37. https://doi.org/10.1111/j.1365-2036.2009.03984.x PMid:19298580
5. Frelinger AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 3;59(14):1304-11. https://doi.org/10.1016/j.jacc.2011.12.024 PMid:22464259
6. Zhang H, Wu F, Zhu J, et al. Physicochemical properties of proton pump inhibitors: implications for formulation development. J Pharm Sci. 2021;110(4):1570-1579.
7. Aslam N, Wright R. Dexlansoprazole MR. Expert Opinion on Pharmacotherapy Vol. 10 2009, Drug Evaluation. p. 2329-36. https://doi.org/10.1517/14656560903198978 PMid:19708852
8. Chaubal CC, Lawate P, Chaudhury S, Gupta A, Shankar BR, Pal S, Patil D. Efficacy and safety of dexlansoprazole: a comprehensive review. Int J Res Med Sci. 2023. https://doi.org/10.18203/2320-6012.ijrms20233741
9. Nunes GP, Silveira TC, Marciano JVS, dos Reis-Prado AH, Ferrisse TM, dos Anjos EB, et al. The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, Vol. 25. Multidisciplinary Digital Publishing Institute (MDPI); 2024 https://doi.org/10.3390/ijms25021247 PMid:38279248 PMCid:PMC10816097
10. Lakshmi Keerthi B, Deepthi R, Srinivasa Rao Y, Varaprasada Rao K. A novel rp-hplc method development and validation for the estimation of dexlansoprazole in bulk and extended-release capsules. World. J Pharm Res. 2021 May 21.
11. Behm BW, Peura DA. Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):439-45. https://doi.org/10.1586/egh.11.37 PMid:21780890
12. Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: The effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor - Evidence for dosing flexibility. Aliment Pharmacol Ther. 2009 Apr;29(8):824-33. https://doi.org/10.1111/j.1365-2036.2009.03979.x PMid:19243357
13. Amala SG, et al. Development of simultaneous-equation UV method for Dexlansoprazole & Aspirin using Vierordt's method. World J Pharm Pharm Sci. 2020;9(5):1820-1830.
14. Abel C, Desilets AR, Willett K. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease. Vol. 44, Annals of Pharmacotherapy. 2010. p. 871-7. https://doi.org/10.1345/aph.1M685 PMid:20371754
15. Roshdy A, Elmansi H, Shalan S, El‐Brashy A. New spectroscopic methods for determination of dexlansoprazole using mercurochrome. Luminescence. 2021 Aug;36(5):1181-8. https://doi.org/10.1002/bio.4043 PMid:33724687
Published
Abstract Display: 734 
PDF Downloads: 486 PDF Downloads: 118 How to Cite
Issue
Section
Copyright (c) 2025 Aditya Ambi , Pravin Wakte , Sachin Bhusari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.